• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用NOTA或RESCA1偶联的uPAR的AE105肽拮抗剂对AlF标记进行优化和评估。

Optimization and Evaluation of AlF Labeling Using a NOTA-or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR.

作者信息

Jeppesen Troels E, Simón Marina, Torp Josephine, Knudsen Line B S, Leth Julie Maja, Crestey François, Ploug Michael, Jørgensen Jesper T, Madsen Jacob, Herth Matthias M, Kjaer Andreas

机构信息

Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.

Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

出版信息

Front Nucl Med. 2021 Dec 13;1:799533. doi: 10.3389/fnume.2021.799533. eCollection 2021.

DOI:10.3389/fnume.2021.799533
PMID:39355634
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11440976/
Abstract

Fluorine-18 displays almost ideal decay properties for positron emission tomography (PET) and allows for large scale production. As such, simplified methods to radiolabel peptides with fluorine-18 are highly warranted. Chelation of aluminium fluoride-18 toward specific peptides represents one method to achieve this. With the current methods, chelation of aluminium fluoride-18 can be achieved using NOTA-conjugated peptides. However, the heating to 90-100◦C that is required for this chelation approach may be deleterious to the targeting moiety of the probe. Recently, a new chelator, RESCA1, was developed allowing AlF chelation at room temperature. Here, we optimize the labeling procedure enabling high chelation efficacy of fluoride-18 at 22◦C, even at full batch labeling. The optimized procedure was tested by AlF-labeling of RESCA1-AE105-a uPAR targeting peptide. NOTA-AE105 was also labeled with AlF, and the two peptides were compared head-to-head. [F]AlF-NOTA-AE105 and [F]AlF-RESCA1-AE105 could be produced in equal radiochemical yields (RCY), radiochemical purities (RCP) and molar activities. Additionally, the two peptides showed comparable binding affinity to uPAR and uptake in cells expressing the uPAR, when evaluated . Overall, we found that the performances of [F]AlF-NOTA-AE105 and [F]AlF-RESCA1-AE105 were grossly comparable, but importantly RESCA1 can be labeled with aluminium fluoride-18 at 22◦C. Consequently, this study showed that RESCA1 is superior to NOTA with respect to AlF chelation of temperature sensitive molecules, such as thermolabile peptides and proteins as well as that full batch chelation of RESCA1 with fluoride-18 is possible.

摘要

氟 - 18在正电子发射断层扫描(PET)中表现出几乎理想的衰变特性,并且能够大规模生产。因此,非常有必要采用简化的方法用氟 - 18对肽进行放射性标记。18氟铝与特定肽的螯合是实现这一目标的一种方法。使用当前的方法,可以通过NOTA共轭肽实现18氟铝的螯合。然而,这种螯合方法所需的90 - 100℃加热可能会对探针的靶向部分造成损害。最近,一种新的螯合剂RESCA1被开发出来,它能够在室温下实现AlF螯合。在此,我们优化了标记程序,即使在全批量标记的情况下,也能在22℃实现氟 - 18的高效螯合。通过将RESCA1 - AE105(一种uPAR靶向肽)用AlF标记来测试优化后的程序。NOTA - AE105也用AlF进行了标记,并将这两种肽进行了直接比较。[F]AlF - NOTA - AE105和[F]AlF - RESCA1 - AE105可以以相同的放射化学产率(RCY)、放射化学纯度(RCP)和摩尔活性生产出来。此外,在评估时,这两种肽对uPAR表现出相当的结合亲和力,并且在表达uPAR的细胞中摄取情况相当。总体而言,我们发现[F]AlF - NOTA - AE105和[F]AlF - RESCA1 - AE105的性能大致相当,但重要的是RESCA1可以在22℃用18氟铝进行标记。因此,本研究表明,在对温度敏感分子(如热不稳定的肽和蛋白质)进行AlF螯合方面,RESCA1优于NOTA,并且RESCA1与氟 - 18的全批量螯合是可行的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc9/11440976/f5ee875c62a5/fnume-01-799533-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc9/11440976/ebc16257afe7/fnume-01-799533-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc9/11440976/025c4dd49d5e/fnume-01-799533-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc9/11440976/bc79bfe2f68d/fnume-01-799533-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc9/11440976/4a317150704f/fnume-01-799533-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc9/11440976/3b34de085485/fnume-01-799533-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc9/11440976/f5ee875c62a5/fnume-01-799533-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc9/11440976/ebc16257afe7/fnume-01-799533-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc9/11440976/025c4dd49d5e/fnume-01-799533-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc9/11440976/bc79bfe2f68d/fnume-01-799533-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc9/11440976/4a317150704f/fnume-01-799533-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc9/11440976/3b34de085485/fnume-01-799533-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebc9/11440976/f5ee875c62a5/fnume-01-799533-g0006.jpg

相似文献

1
Optimization and Evaluation of AlF Labeling Using a NOTA-or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR.使用NOTA或RESCA1偶联的uPAR的AE105肽拮抗剂对AlF标记进行优化和评估。
Front Nucl Med. 2021 Dec 13;1:799533. doi: 10.3389/fnume.2021.799533. eCollection 2021.
2
First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.首个用于 uPAR 的正电子发射断层扫描(PET)成像的 18F 标记配体:在人前列腺癌异种移植模型中的体内研究。
Nucl Med Biol. 2013 Jul;40(5):618-24. doi: 10.1016/j.nucmedbio.2013.03.001. Epub 2013 Apr 18.
3
Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.尿激酶型纤溶酶原激活物受体作为胶质母细胞瘤潜在的正电子发射断层显像生物标志物
J Nucl Med. 2016 Feb;57(2):272-8. doi: 10.2967/jnumed.115.161703. Epub 2015 Oct 1.
4
Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies.使用新型(64)Cu 标记的交叉桥连肽配体改善 uPAR 表达的 PET 成像:体外和体内比较研究。
Theranostics. 2013 Aug 3;3(9):618-32. doi: 10.7150/thno.6810. eCollection 2013.
5
68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.68Ga 标记及体内评价一种用于侵袭性癌症 PET 成像的 uPAR 结合的 DOTA 和 NODAGA 缀合肽。
Nucl Med Biol. 2012 May;39(4):560-9. doi: 10.1016/j.nucmedbio.2011.10.011. Epub 2011 Dec 14.
6
Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with F-FDG PET/CT: A Single-Center Prospective Study.尿激酶型纤溶酶原激活物受体 PET/CT 对头颈部鳞状细胞癌的预后价值及与 F-FDG PET/CT 的比较:一项单中心前瞻性研究。
J Nucl Med. 2022 Aug;63(8):1169-1176. doi: 10.2967/jnumed.121.262866. Epub 2021 Dec 2.
7
Hexavalent lactoside labeled with [F]AlF for PET imaging of asialoglycoprotein receptor.六价乳糖标记 [F]AlF 用于通过正电子发射断层扫描成像法对糖蛋白受体进行成像。
Appl Radiat Isot. 2020 Aug;162:109199. doi: 10.1016/j.apradiso.2020.109199. Epub 2020 Apr 25.
8
Second generation AlF-labeled D-amino acid peptide for CXCR4 targeted molecular imaging.第二代 AlF 标记的 D-氨基酸肽用于 CXCR4 靶向分子成像。
Nucl Med Biol. 2024 May-Jun;132-133:108906. doi: 10.1016/j.nucmedbio.2024.108906. Epub 2024 Mar 19.
9
A novel urokinase plasminogen activator receptor-targeted peptide-based probe for in-vivo molecular imaging of glioblastoma.一种新型的基于靶向尿激酶型纤溶酶原激活剂受体肽的探针,用于胶质母细胞瘤的体内分子成像。
Nucl Med Commun. 2023 Feb 1;44(2):142-149. doi: 10.1097/MNM.0000000000001644. Epub 2022 Dec 16.
10
Optimized labeling of NOTA-conjugated octreotide with F-18.用F-18对NOTA偶联的奥曲肽进行优化标记。
Tumour Biol. 2012 Apr;33(2):427-34. doi: 10.1007/s13277-011-0250-x. Epub 2011 Oct 19.

引用本文的文献

1
Targeted imaging of uPAR expression in vivo with cyclic AE105 variants.用环 AE105 变体在体内靶向成像 uPAR 表达。
Sci Rep. 2023 Oct 11;13(1):17248. doi: 10.1038/s41598-023-43934-w.

本文引用的文献

1
Determination of Binding Kinetics of Intrinsically Disordered Proteins by Surface Plasmon Resonance.利用表面等离子体共振测定内源性无序蛋白质的结合动力学。
Methods Mol Biol. 2020;2141:611-627. doi: 10.1007/978-1-0716-0524-0_31.
2
AlF-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging.用于正电子发射断层成像的热敏感生物分子的铝氟标记
Theranostics. 2017 Jul 14;7(11):2924-2939. doi: 10.7150/thno.20094. eCollection 2017.
3
Improved positron emission tomography imaging of glioblastoma cancer using novel Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR).
使用靶向尿激酶型纤溶酶原激活剂受体(uPAR)的新型镓标记肽改善胶质母细胞瘤的正电子发射断层扫描成像。
Amino Acids. 2017 Jun;49(6):1089-1100. doi: 10.1007/s00726-017-2407-4. Epub 2017 Mar 18.
4
A Manganese Alternative to Gadolinium for MRI Contrast.一种用于磁共振成像造影的替代钆的锰剂
J Am Chem Soc. 2015 Dec 16;137(49):15548-57. doi: 10.1021/jacs.5b10748. Epub 2015 Dec 4.
5
Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.尿激酶型纤溶酶原激活物受体作为胶质母细胞瘤潜在的正电子发射断层显像生物标志物
J Nucl Med. 2016 Feb;57(2):272-8. doi: 10.2967/jnumed.115.161703. Epub 2015 Oct 1.
6
Setup and validation of shake-flask procedures for the determination of partition coefficients (logD) from low drug amounts.用于从低药物量测定分配系数(logD)的摇瓶法的建立与验证。
Eur J Pharm Sci. 2015 Aug 30;76:181-91. doi: 10.1016/j.ejps.2015.05.008. Epub 2015 May 9.
7
18F-Labeled Peptides: The Future Is Bright.18F标记的肽类:前景光明。
Molecules. 2014 Dec 8;19(12):20536-20556. doi: 10.3390/molecules191220536.
8
PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature.用于神经内分泌肿瘤生长抑素受体成像的正电子发射断层显像(PET)示踪剂:现状及文献综述
Future Oncol. 2014 Nov;10(14):2259-77. doi: 10.2217/fon.14.139.
9
First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.首个用于 uPAR 的正电子发射断层扫描(PET)成像的 18F 标记配体:在人前列腺癌异种移植模型中的体内研究。
Nucl Med Biol. 2013 Jul;40(5):618-24. doi: 10.1016/j.nucmedbio.2013.03.001. Epub 2013 Apr 18.
10
Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction.尿激酶受体功能的构象调节:受体占据和表位映射单克隆抗体对片状伪足诱导的影响。
J Biol Chem. 2011 Sep 23;286(38):33544-56. doi: 10.1074/jbc.M111.220087. Epub 2011 Jul 28.